Drug Database
Back to search

Poland· PL-100220365

Elestar

A olmesartan medoxomil und amlodipin product containing olmesartanum medoxomilum + amlodipinum, registered in Poland by Menarini International Operations Luxembourg S.A.. The same ATC class is registered in 8 of our 19 countries.

ATC C09DB02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedElestarATCC09DB02REGISTER NO.PL-100220365PACKS LISTED7CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about olmesartanum medoxomilum + amlodipinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Olmesartan medoxomil und amlodipin is registered in 8 of 19 countries.

Countries holding a registration under ATC C09DB02 (olmesartan medoxomil und amlodipin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search olmesartan medoxomil und amlodipin products by name

Olmesartan medoxomil und amlodipin · ATC C09DB02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Olmesartanum medoxomilum + Amlodipinum
Manufacturer
Menarini International Operations Luxembourg S.A.
Country
Poland (PL)
ATC code
C09DB02
ATC class
Olmesartan medoxomil und Amlodipin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 7

  • gtin
    05909990750542
  • gtin
    05909990750559
  • gtin
    05909990750566
  • gtin
    05909990750573
  • gtin
    05909990750580
  • gtin
    05909990750597
  • gtin
    05909990750603

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for olmesartan medoxomil und amlodipin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check olmesartan medoxomil und amlodipin against other medicinesHow interaction checks work

Olmesartan medoxomil und amlodipin · interactions on record

81 records

81 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Olmesartan medoxomil und amlodipin in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All olmesartan medoxomil und amlodipin products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Belgium · Olmesartan/Amlodipine Eg
  • Bulgaria · Олмезид Am
  • Germany · Olmesartan/Amlodipin Al
  • Spain · Olmesartán/Amlodipino Stada
  • Ireland · Olmesartan/Amlodipine Clonmel
  • Italy · Olmesartan E Amlodipina Eg
  • Luxembourg · Olmesartan/Amlodipine Eg
  • Netherlands · Olmesartanmedoxomil/Amlodipine Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/71478f07-1094-4814-a2ea-e31aaa232a08
GET /v1/drugs/71478f07-1094-4814-a2ea-e31aaa232a08?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "40 mg + 10 mg",
  "packaging": "05909990750542 ¦ Rp ¦ 55066\n10 tabl.\n05909990750559 ¦ Rp ¦ 55067\n14 tabl.\n05909990750566 ¦ Rp ¦ 55068\n28 tabl.\n05909990750573 ¦ Rp ¦ 55069\n50 tabl.\n05909990750580 ¦ Rp ¦ 55070\n56 tabl.\n05909990750597 ¦ Rp ¦ 55071\n98 tabl.\n05909990750603 ¦ Rp ¦ 55072\n500 tabl.",
  "substance": "Olmesartanum medoxomilum 40 mg + Amlodipinum 10 mg",
  "common_name": "Olmesartanum medoxomilum + Amlodipinum",
  "pl_product_id": "100220365",
  "pozwolenie_nr": "16193",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about olmesartan medoxomil und amlodipin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console